Key Highlights
- Masks and accessories grew 15% in the March 2026 quarter versus 9% for devices, the mix shift that underpins both Margin expansion and the recurring-revenue thesis.
- Non-GAAP EPS rose 21% on 11% Revenue growth with gross margin up 290 basis points, evidence of real Operating Leverage rather than financial engineering.
- The stock's 23.95% twelve-month decline is a multiple de-rating driven by the GLP-1 debate, not by reported operating deterioration.
- ResMed agreed to sell MatrixCare, the post-acute and senior-living software Business inside its Residential Care Software segment, to Private Equity firm Frazier Healthcare Partners.
A portfolio reshuffle, days before the year-end print
ResMed (NYSE:RMD) agreed to sell MatrixCare, the post-acute and senior-living software business inside its Residential Care Software segment, to private equity firm Frazier Healthcare Partners. Chief executive Mick Farrell described the decision as "disciplined Portfolio Management ," aimed at areas with the "greatest opportunity for sleep health innovation and impact." MatrixCare serves more than 15,000 skilled nursing, senior living, home health and hospice providers, and the HEALTHCAREfirst and Citus brands go with it; Brightree in the United States and MEDIFOX DAN in Germany stay. Terms were not disclosed, though MassDevice reported the price at $490 million in cash. Completion is expected in the first quarter of fiscal 2027.
Timing sharpens the stakes. The fiscal year ended June 30, and fourth-quarter and full-year 2026 results are scheduled for the latest session, unreported as of August 1. Investors are pricing a business whose most recent disclosed quarter is four months old.
The tape and the income statement disagree
Shares closed at $210.98, according to aggregated market data, capping a 4.9% advance across July from $201.10 that included four consecutive gains in the final week. That still leaves the stock about 28% below its 52-week high of $293.81, only modestly above the $180.27 low, and down 23.95% over twelve months. Market Capitalization is $30.43 billion.
The path was not smooth. Shares fell 6.33% on July 8, the session after the MatrixCare announcement, a reaction suggesting the market read the divestiture as shrinking the recurring-revenue base rather than sharpening it. The twelve-month decline is harder to square with operations, since revenue and Earnings both grew through the period. What compressed was the multiple, not the business.
Masks, not machines, carry the thesis
The company sells flow-generator devices for obstructive sleep apnea and chronic obstructive pulmonary disease, the masks and tubing that attach to them, and the cloud software, AirView, myAir, that tracks adherence. The fiscal 2025 Annual Report puts devices at roughly 52% of net revenue, masks, diagnostic products and accessories at about 36%, and Residential Care Software at about 12%.
The Investment case rests on the second bucket. A device is sold once; masks and cushions wear out and get replaced, generating a recurring stream tied to the cumulative installed base rather than to new patient starts. That Annuity separates ResMed from a conventional capital-equipment story.
What the last reported quarter showed
Fiscal third-quarter revenue, for the three months ended reached $1,431.4 million, up 11% as reported and 8% in constant currency. Masks and accessories grew 15% to $524.8 million, comfortably ahead of devices at $735.7 million, up 9%. Residential Care Software added $170.9 million. Americas revenue rose 9% to $818.7 million; Europe, Asia and other markets rose 16% as reported but 7% in constant currency, a gap that flags how much of the headline came from a weaker dollar.
Profitability is where the quarter stood out. GAAP gross margin expanded 290 basis points to 62.2%, which management attributed primarily to component cost improvements and Manufacturing and logistics efficiencies. GAAP Operating Income rose 17% to $499.8 million even as selling, general and administrative expense climbed 16% on the VirtuOx Acquisition and technology spending. Non-GAAP Diluted Earnings per Share of $2.86 grew 21%, genuine operating leverage rather than buyback arithmetic.
Operating Cash Flow was $554 million in the quarter and $1,351.2 million across nine months. ResMed ended March with $1,660.5 million in cash against $664.1 million of Debt , returned $175 million through Buybacks and $87 million in dividends, and lifted the quarterly payout 13% to $0.60.
Building past the CPAP box
Management is widening the definition of sleep health. In June 2026 ResMed completed the acquisition of Noctrix Health, reported by MassDevice at $340 million, bringing in Nidra tonic motor activation therapy, a wearable with FDA De Novo authorization for moderate-to-severe restless legs syndrome in medication-refractory patients. RLS affects roughly 8% of adults, and the therapy carries American Academy of Sleep Medicine guideline inclusion. The FDA also cleared ResMed's AI-driven Smart Comfort personalization in December 2025, and a May 2026 Partnership with wearable maker Oura pushes screening Upstream toward consumers who have never seen a sleep physician.
Reimbursement remains the constraint: the annual report notes Medicare competitive bidding has already cut payment for CPAP devices and related supplies in both bidding and non-bidding areas.
The case for a compounder
Gross margin has moved from 59.4% in fiscal 2025 to 61.6% on a trailing basis, and each point of mix shift toward masks helps. Returns are strong for a business trading at a market multiple, Return on Equity of 25.3%, return on invested capital of 26.9%, net cash of roughly $817 million. Analysts modeling $5.65 billion of fiscal 2026 revenue and $11.12 of EPS expect earnings to grow at nearly double the revenue rate.
Where the argument breaks down
The GLP-1 overhang is real and the company acknowledges it. ResMed's own filing states that GLP-1 weight-loss drugs "may lower the occurrence of obesity, eventually reducing the severity of OSA, if significant weight loss is maintained," and notes such drugs are already approved for OSA in obese patients with moderate-to-severe disease. No collapse in patient flow is visible yet, device revenue still grew 9% in the March quarter, and the third-quarter release carried no GLP-1 commentary, but the market is discounting a terminal-growth question that current results cannot settle.
Competition has also normalized. The fiscal 2025 filing lists Philips BV first among Sleep and Breathing Health rivals, alongside Fisher & Paykel, React Health and BMC; the extraordinary share gains captured while Philips Respironics was sidelined are unlikely to repeat. Tariffs add another unknown: the company warned that measures introduced in February 2025 could drive supply-chain Inflation , while noting US Customs confirmed continuing relief for its product category in April 2025.
Valuation and the road to August 6
At $210.98, ResMed trades at 20.1 times trailing earnings and 17.6 times forward estimates, with a price-to-sales ratio of 5.47, price-to-free-cash-flow of 17.3 and a free-cash-flow Yield of 5.79%. Enterprise value is $29.46 billion against $5.54 billion of trailing revenue. Those are undemanding numbers for a business compounding earnings in the mid-to-high teens, reflecting a de-rating rather than deteriorating fundamentals. The consensus target of $248.60 spans a wide $180 to $325, itself a statement about how unresolved the GLP-1 question is.
August 6 brings the next real data point: full-year fiscal 2026 numbers, commentary on the MatrixCare disposal's financial impact, and management's first live read on device Demand in four months. Whether mask growth keeps outpacing devices is the number that will tell investors most.
Upcoming Catalysts
- Fiscal Q4 and full-year 2026 results. First disclosure of June-quarter device and mask trends, full-year margins, and any commentary on the MatrixCare transaction's financial effect.
- MatrixCare sale close, expected fiscal Q1 2027. Confirmation of proceeds, the resulting gain or loss, and how capital is redeployed.
- Noctrix commercial rollout through fiscal 2027. Early evidence on whether restless legs syndrome becomes a meaningful second sleep Franchise or stays a small adjacency.
- New CFO transition. Aaron Bloomer succeeds retiring CFO Brett Sandercock, with guidance philosophy and capital-allocation priorities to be set out.
Principal Risks
- GLP-1 substitution. ResMed's own annual report concedes sustained weight loss could reduce OSA severity. If new-patient starts slow materially, the installed base, and therefore the mask annuity, grows more slowly.
- Reimbursement pressure. Medicare competitive bidding has already cut CPAP and supplies payment in both bidding and non-bidding areas, constraining pricing for Downstream providers who buy ResMed's products.
- Currency dependence. Third-quarter international revenue grew 16% as reported but only 7% in constant currency; a stronger dollar would remove a large share of headline growth.
- Tariffs and Supply chain. The company has warned that widespread reciprocal tariffs could materially affect its business through supply-chain interruption, despite current relief for its product category.
- Portfolio churn execution. Selling MatrixCare while buying Noctrix and VirtuOx increases integration and disposal risk; the 6.33% drop showed the market is not automatically crediting the strategy.
Conclusion
Masks and accessories grew 15% in the March 2026 quarter versus 9% for devices, the mix shift that underpins both margin expansion and the recurring-revenue thesis. Set against that: ResMed's own annual report concedes sustained weight loss could reduce OSA severity. That tension shows up in the valuation: The stock's 23.95% twelve-month decline is a multiple de-rating driven by the GLP-1 debate, not by reported operating deterioration. The next real test: First disclosure of June-quarter device and mask trends, full-year margins, and any commentary on the MatrixCare transaction's financial effect.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.






Please wait processing your request...